In the randomized phase II AdvanTIG-203 trial, adding the anti-TIGIT antibody ociperlimab to tislelizumab did not improve response rates or survival in advanced esophageal squamous cell carcinoma. The study tested whether combining immune checkpoint blockade with TIGIT inhibition could deepen benefit; results were negative on both efficacy outcomes reported. The data further narrows the clinical pathway for TIGIT approaches in unselected advanced settings, emphasizing the ongoing challenge of converting immunologic rationale into survival gains.